Dilatation of the main pancreatic duct of unknown origin: causes and risk factors of pre-malignancy or malignancy

被引:3
|
作者
Martin, Antoine [1 ]
Cros, Jerome [1 ]
Vullierme, Marie-Pierre [1 ]
Dokmak, Safi [1 ]
Sauvanet, Alain [1 ]
Levy, Philippe [1 ]
Rebours, Vinciane [1 ]
Maire, Frederique [1 ]
机构
[1] Hop Beaujon, Pole Malad Appareil Digest, Clichy, France
关键词
Dilatation of the main pancreatic duct; Pancreatic adenocarcinoma; IPMN; PanIN; Pancreatic nodule; PAPILLARY MUCINOUS NEOPLASMS; GUIDELINES; MANAGEMENT; SYSTEM; TUMORS; IPMN;
D O I
10.1007/s00464-022-09854-y
中图分类号
R61 [外科手术学];
学科分类号
摘要
IntroductionA dilatation of the main pancreatic duct (MPD) is mainly due to obstructive causes (pancreatic tumor, chronic pancreatitis) or intraductal papillary mucinous neoplasm (IPMN). This study aims to assess the risk of pre-malignancy or malignancy in case of MPD dilatation with no visible mass nor obstructive calcification on computed tomography scan (CT-scan) in a population operated for it.Patients and methodsAll patients operated on from November 2015 to December 2019 in our center for a significant dilatation of the MPD without visible obstructive cause on CT-scan were included. Preoperative work-up included at least CT-scan, magnetic resonance imaging (MRI), and endoscopic ultrasonography (EUS). Primary endpoint was the final pathological diagnosis. Secondary endpoints were predictive factors of malignancy.Results101 patients were included, mean age 68 years-old. Final pathological data were pancreatic adenocarcinoma (n = 2), IPMN with high-grade dysplasia (n = 37), high-grade Pancreatic Intraepithelial Neoplasia (PanIN) (n = 2) (total of pre-malignant or malignant lesions: n = 41), neuroendocrine tumor (n = 6), IPMN with low-grade dysplasia (n = 45), low-grade PanIN (n = 5), chronic pancreatitis (n = 3), and benign stenosis (n = 1). On preoperative explorations, the median diameter of MPD was 7 mm [3-35]. MRI and/or EUS showed intraductal material, nodule, or cyst in 22, 32, and 52 patients, respectively; 22 patients without nodule visible on MRI or EUS had still a pre-malignant or malignant lesion. In multivariate analysis, predictive factors for pre-malignancy or malignancy were symptoms before surgery (p = 0.01), MPD dilatation without downstream stenosis (p = 0.046), and the presence of nodule (p = 0.009).ConclusionA dilatation of the MPD without detectable mass or obstructive calcification on CT-scan was associated with a pre-malignant or malignant lesion in 41 patients. Symptoms before surgery, MPD dilatation without duct narrowing, and the presence of nodules on MRI/EUS were associated with the risk of pre-malignancy or malignancy.
引用
收藏
页码:3684 / 3690
页数:7
相关论文
共 50 条
  • [1] Dilatation of the main pancreatic duct of unknown origin: causes and risk factors of pre-malignancy or malignancy
    Antoine Martin
    Jérôme Cros
    Marie-Pierre Vullierme
    Safi Dokmak
    Alain Sauvanet
    Philippe Levy
    Vinciane Rebours
    Frédérique Maire
    [J]. Surgical Endoscopy, 2023, 37 : 3684 - 3690
  • [2] DILATATION OF THE MAIN PANCREATIC DUCT: CAUSES AND RISK FACTORS OF MALIGNANCY
    Martin, Antoine
    Cros, Jerome
    Vullierme, Marie-Pierre
    Dokmak, Safi
    Aussilhou, Beatrice
    Sauvanet, Alain
    Levy, Philippe
    Rebours, Vinciane
    Maire, Frederique
    [J]. GASTROENTEROLOGY, 2021, 160 (06) : S479 - S480
  • [3] Risk of Pre-Malignancy or Malignancy in Postmenopausal Endometrial Polyps: A CHAID Decision Tree Analysis
    Wong, Michael
    Thanatsis, Nikolaos
    Nardelli, Federica
    Amin, Tejal
    Jurkovic, Davor
    [J]. DIAGNOSTICS, 2021, 11 (06)
  • [4] Pancreatic Duct Strictures: Identifying Risk of Malignancy
    Matthew F. Kalady
    Bercedis Peterson
    John Baillie
    Mark W. Onaitis
    Omar I. Abdul-Waha
    James K. Howden
    Paul S. Jowell
    M. Stan Branch
    Bryan M. Clary
    Theodore N. Pappas
    Douglas S. Tyler
    [J]. Annals of Surgical Oncology, 2004, 11 : 581 - 588
  • [5] Pancreatic duct strictures: Identifying risk of malignancy
    Kalady, MF
    Peterson, B
    Baillie, J
    Onaitis, MW
    Abdul-Wahab, OI
    Howden, JK
    Jowell, PS
    Branch, MS
    Clary, BM
    Pappas, TN
    Tyler, DS
    [J]. ANNALS OF SURGICAL ONCOLOGY, 2004, 11 (06) : 581 - 588
  • [6] VILLOUS ADENOMA OF THE MAIN PANCREATIC DUCT - A CLUE TO THE PATHOGENESIS OF PANCREATIC MALIGNANCY
    SHRAGER, JB
    GREELISH, J
    VANARSDALE, C
    FURTH, E
    DALY, JM
    [J]. SURGICAL ONCOLOGY-OXFORD, 1994, 3 (04): : 203 - 210
  • [7] Main pancreatic duct dilatation: a sign of high risk for pancreatic cancer
    Tanaka, S
    Nakaizumi, A
    Ioka, T
    Oshikawa, O
    Uehara, H
    Nakao, M
    Yamamoto, K
    Ishikawa, O
    Ohigashi, H
    Kitamra, T
    [J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2002, 32 (10) : 407 - 411
  • [8] Isolated main pancreatic ductal dilatation detected by computed tomography: When to be concerned for malignancy?
    Patel, Amil
    Okoro, Ngozi
    Parekh, Samir
    Han, Yoosun
    Cai, Qiang
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2006, 101 (09): : S114 - S115
  • [9] Main pancreatic duct involved IPMN without high-risk factors: how to judge the degree of malignancy based on MPD dilation?
    Zhu, Yong
    Mao, Yingfan
    Wang, Jianhua
    Wang, Zhongqiu
    Chen, Xiao
    [J]. MEDICINE, 2024, 103 (33)
  • [10] Enhancing Mural Nodule in the Main Pancreatic Duct of Main and Mixed Type IPMN of the Pancreas: Does Size Matter on Malignancy Risk?
    Kim, T. H.
    [J]. PANCREAS, 2019, 48 (10) : 1462 - 1462